Rocket


Overview
Financials
News + Filings
Key Docs
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
ASLAN Pharmaceuticals Ltd (ASLN) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/18/2023 6-K/A Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]
08/11/2023 6-K Quarterly results
Docs: "6-K",
"ASLAN PHARMACEUTICALS REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Positive topline data reported in July from TREK-AD, a Phase 2b study of eblasakimab that met the primary endpoint across three dose arms with statistical significance. The data established eblasakimab, a potential first-in-class antibody, as the first biologic in moderate-to-severe atopic dermatitis to demonstrate a competitive efficacy profile with once-monthly dosing from initiation - Data supports advancement of eblasakimab into Phase 3 clinical development program in 2024 - Readouts from TREK-DX Phase 2 study of eblasakimab and FAST-AA Phase 2a study of farudodstat both expected in the first quarter of 2024 - Company maintains healthy operating position with $40.9 million in cash and ca..."
07/20/2023 6-K Quarterly results
07/13/2023 SC 13G/A TANG CAPITAL PARTNERS LP reports a 11% stake in ASLAN Pharmaceuticals Limited
07/06/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Opinion of Walkers (Singapore) Limited Liability Partnership, Cayman Islands counsel to the Company",
"Opinion of Walkers (Singapore) Limited Liability Partnership, Cayman Islands counsel to the Company"
07/06/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
07/06/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"EBLASAKIMAB MONTHLY DOSING SHOWS POTENTIAL FOR BEST-IN-CLASS THERAPY IN POSITIVE PHASE 2B STUDY IN ATOPIC DERMATITIS - Eblasakimab is the first biologic in moderate-to-severe atopic dermatitis to demonstrate a competitive efficacy profile with once-monthly dosing from initiation comparable to once every two weeks, supporting advancement to Phase 3. - 600mg eblasakimab dosed once every four weeks in the TREK-AD study met the primary endpoint with statistical significance, with 62.7% of patients achieving EASI-75, 34.1% reaching EASI-90 and 31.2% achieving vIGA-AD of 0 or 1. - Regimens dosing once every two weeks also met the primary endpoint with statistical significance, as well as meeting key secondary endpoints. - Unique loading dose regimen observed to deliver rapid onset of action with..."
07/03/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Amendment No. 1 to Warrant to Purchase Ordinary Shares",
"First Amendment to Loan, Guaranty and Security Agreement, by and among ASLAN Pharmaceuticals Limited, ASLAN Pharmaceuticals (USA) Inc., ASLAN Pharmaceuticals Ptd. Ltd., and K2 HealthVentures LLC"
04/28/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"PRESS RELEASE"
04/26/2023 F-6EF Form F-6EF - Registration of American Depository Receipt shares, immediately effective:
04/26/2023 D Form D - Notice of Exempt Offering of Securities:
03/24/2023 F-3 Form F-3 - Registration statement by foreign private issuers:
03/24/2023 F-3 Form F-3 - Registration statement by foreign private issuers:
03/24/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/24/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"PRESS RELEASE"
03/20/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
03/10/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"ASLAN PHARMACEUTICALS ANNOUNCES PLAN TO IMPLEMENT ADS RATIO CHANGE San Mateo, California, and Singapore, March 10, 2023 – ASLAN Pharmaceuticals , a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it plans to change the ratio of the American Depositary Shares to its ordinary shares, par value $0.01 per share, from one ADS representing five ordinary shares to one ADS representing twenty-five ordinary shares. For the Company’s existing ADS holders, the change in the ADS ratio will have the same effect as a one-for-five reverse ADS split. There will be no change to the Company’s ordinary shares. The effect of the ratio change on the ADS trading price on the Nasdaq Capital Market is expected t..."
03/06/2023 SC 13G BIOTECHNOLOGY VALUE FUND L P has filed a Schedule 13D for ASLAN Pharmaceuticals Limited
03/03/2023 F-6 POS Form F-6 POS - Post-effective amendments for immediately effective filing:
02/24/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Unit Purchase Agreement dated February 24, 2023, by and among ASLAN Pharmaceuticals Limited and the Purchasers named therein",
"Form of Pre-Funded Warrant",
"Form of Tranche 1A Warrant",
"Form of Tranche 1B Warrant",
"Form of Tranche 2A Warrant",
"Form of Tranche 2B Warrant"
02/14/2023 SC 13G/A TANG CAPITAL PARTNERS LP reports a 7.8% stake in ASLAN Pharmaceuticals Limited
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/31/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Companies Act")."
01/04/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"ASLAN PHARMACEUTICALS AND THERMO FISHER SCIENTIFIC ANNOUNCE PARTNERSHIP TO MANUFACTURE HIGH CONCENTRATION FORMULATION OF EBLASAKIMAB FOR FUTURE STUDIES - Thermo Fisher Scientific to provide biologic manufacturing expertise and scale-up capacity to manage the clinical supply of eblasakimab for future Phase 3 studies - A high concentration formulation of eblasakimab will be manufactured which could enable doses of up to 400mg eblasakimab to be delivered via a single subcutaneous injection San Mateo, California, and Singapore, January 3, 2023 –"
12/21/2022 6-K Quarterly results
11/03/2022 CT ORDER Form CT ORDER - Confidential treatment order:
11/03/2022 CT ORDER Form CT ORDER - Confidential treatment order:
10/28/2022 6-K Quarterly results
09/28/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
09/14/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"PRESS RELEASE ASLAN PHARMACEUTICALS COMMENCES CLINICAL PROGRAM TO STUDY EBLASAKIMAB IN DUPILUMAB-EXPERIENCED ATOPIC DERMATITIS PATIENTS -"
09/13/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"SCHEDULE 1 LIST OF DOCUMENTS EXAMINED 1. The Certificate of Incorporation dated 23 June 2014, the Tenth Amended and Restated Memorandum and Articles of Association as adopted on 16 November 2020 by special resolution passed on 4 September 2020 , Register of Members and Register of Directors, in each case, of the Company, copies of which have been provided to us by its registered office in the Cayman Islands and/or the Company's advisers . 2. A copy of a Certificate of Good Standing dated 9 September 2022 in respect of the Company issued by the Registrar . 3. Copies of executed minutes of meetings of the Board of Directors of the Company dated, respectively, 10 September 2018, 7 November 2018, 6 January 2019, 26 April 2019, 13 May 2019, 30 September 2019, 4 October 2019, 17 July 2020 and 7 ...",
"AMENDMENT NO. 1 TO THE OPEN MARKET SALE AGREEMENTSM"
09/13/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
09/08/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"ASLAN PHARMACEUTICALS PRESENTS NEW DATA ON EBLASAKIMAB IN MULTIPLE POSTERS AT THE 31st ANNUAL EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY CONGRESS • Data presented at EADV for the first time show eblasakimab suppresses downstream inflammatory biomarkers of atopic dermatitis, continuing 4-6 weeks after the last dose • Notable improvements in quality-of-sleep measures, with fewer patients reporting sleep disturbance on eblasakimab • Eblasakimab significantly reduced P-NRS scores and improvements continued throughout 8-week course of treatment across all dose cohorts California and Singapore, September 7, 2022 – ASLAN Pharmaceuticals , a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, to..."
08/12/2022 6-K Quarterly results
Docs: "FORM 6-K",
"ASLAN PHARMACEUTICALS REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE",
"ASLAN Pharmaceuticals Limited Financial Statements for the six months ended June 30, 2022"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy